|
1) Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hyper-tension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007; 369: 1431-9
|
|
|
|
2) Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens. 2000; 13: 461-7
|
|
|
|
|
|
3) Fukui T, Rahman M, Hayashi K, et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res. 2003; 26: 979-90
|
|
|
|
|
4) The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res. 2005; 28: 513-20
|
|
|
|
|
|
5) Ogihara T, Hiwada K, Morimoto S, et al. Guidelines for treatment of hypertension in the elderly--2002 revised version. Hypertens Res. 2003; 26: 1-36
|
|
|
|
|
|
6) Mochizuki S, Shimizu M, Taniguchi I, et al. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. Cardiovasc Drugs Ther. 2004; 18: 305-9
|
|
|
|
|
|
7) Staessen JA, Richart T. Sum and substance in the Jikei Heart Study. Lancet. 2007; 369: 1407-8
|
|
|
|
|